- Open
- 6.05
- High
- 6.30
- Low
- 6.05
- Close
- 6.27
- Change
- +0.15 (2.48%)
- Volume
- 3,666,878
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma is a clinical-stage pharmaceutical company that specializes in infectious diseases. Their clinical model is designed to be more cost-effective than traditional biotech models.
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma is a clinical-stage pharmaceutical company that specializes in infectious diseases. Their clinical model is designed to be more cost-effective than traditional biotech models.
| 14 Jul 2026 |
| Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress |
| 13 Jul 2026 | Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial |
| 13 Jul 2026 | Poolbeg Pharma doses first patient in TOPICAL clinical trial |
| 13 Jul 2026 | Poolbeg Pharma doses first patient in CRS prevention trial at The Christie |
| 13 Jul 2026 | Poolbeg doses first patient in cancer immunotherapy safety trial |
| 30 Jun 2026 | Poolbeg Pharma secures South African patent for lead drug candidate |
| 14 Jul 2026 |
| Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress |
| 13 Jul 2026 | Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial |
| 13 Jul 2026 | Poolbeg Pharma doses first patient in TOPICAL clinical trial |
| 13 Jul 2026 | Poolbeg Pharma doses first patient in CRS prevention trial at The Christie |
| 13 Jul 2026 | Poolbeg doses first patient in cancer immunotherapy safety trial |
| 30 Jun 2026 | Poolbeg Pharma secures South African patent for lead drug candidate |
